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Background/aim: SARS-CoV-2, a ribonucleic acid coronavirus, rapidly spread worldwide within a short timeframe. Although different
antiviral, antiinflammatory, and immunomodulatory drugs are used, current evidence is insufficient as to which drug is more efficient.
Our study compared favipiravir and lopinavir/ritonavir (LPV/RTV) therapies in inpatient care for coronavirus disease 2019 (COVID-19)
pneumonia.
Materials and methods: Demographic data, test results, treatments, and latest status of patients receiving inpatient COVID-19
pneumonia therapy were recorded. The initial favipiravir and LPV/RTV receiving groups were compared regarding the need for intensive
care units (ICU) and mortality. Logistic regression analysis was performed by including variables showing significant differences as a
result of paired comparisons into the model.
Results: Of the 204 patients with COVID-19 pneumonia, 59 (28.9%), 131 (64.2%), and 14 were administered LPV/RTV, favipiravir,
and favipiravir with LPV/RTV, respectively. No difference was found in age, sex, presence of comorbidity, and tocilizumab, systemic
corticosteroid, and plasma therapy use between patients administered with these three different treatment regimens. The mean mortality
age of the patients was 71 ± 14.3 years, which was substantially greater than that of the survivors (54.2 ± 15.5 years). Compared with
patients administered with LPV/RTV, ICU admission and mortality rates were lower in patients administered with favipiravir. CK-MB,
AST, CRP, LDH, and creatinine levels were higher, whereas lymphocyte counts were lower in patients who died. Age, AST, CRP, LDH,
and neutrophil counts were higher in patients needing ICU, and eosinophil and lymphocyte counts were significantly lower. Logistic
regression analysis showed that favipiravir use independently decreased mortality (p = 0.006).
Conclusion: The use of favipiravir was more effective than LPV/RTV in reducing mortality in hospitalized patients with COVID-19.
Key words: COVID-19, pneumonia, favipravir, lopinavir/ritonavir, mortality

1. Introduction
Coronavirus disease 2019 (COVID-19) is a pandemic
that emerged at the end of 2019, caused by SARSCoV-2. SARS-CoV-2 is a newly detected virus and it is
transmitted through the respiratory tract with droplets
and aerosols emitted by an infected person. COVID-19
is characterized by a wide clinical spectrum, ranging
from mild flu-like symptoms to severe acute respiratory
distress syndrome and death [1]. The COVID-19 virus
has infected more than 71 million people worldwide and
caused more than one and a half million deaths as of
December 14, 2020.

Although many treatments have been tried, no specific
drug can currently prevent infection and treat COVID-19
[2]. Most of the available data for pharmacological
treatments were derived from drugs used during
SARS-CoV or MERS-CoV outbreaks or from in vitro
observations. Various clinical and experimental studies
on possible treatments for COVID-19, such as antiviral
(lopinavir/ritonavir [LPV/RTV], favipiravir, remdesivir,
and arbidol), antiinflammatory (hydroxychloroquine and
tocilizumab), and immunomodulatory drugs, stem cell
therapy, and antioxidants are ongoing [1,2]. There are no
clear data on their superiority to each other; therefore, drug
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preferences vary by country. The serious consequences of
the SARS-CoV-2 pandemic in terms of global health and
economics are continuing, and therefore, evidence-based
clinical research and sharing of experiences are needed
to reduce the spread of the disease and to find the most
appropriate treatment options.
Our study aimed to compare the results of LPV/RTV
combination and favipiravir treatment in hospitalized
patients with COVID-19.
2. Materials and methods
Our study retrospectively evaluated 204 patients with
COVID-19 who received inpatient treatment between
March 30, 2020 and September 30, 2020 in our hospital.
The patients’ age, sex, comorbidity, smoking history, length
of hospital stays and treatments used, ICU needs, and
mortality status were recorded. Besides, complete blood
count, biochemistry test results, blood coagulation tests,
liver, and kidney function tests, electrolytes, C-reactive
protein, procalcitonin, lactate dehydrogenase, d-dimer,
and plasma fibrinogen results were evaluated.
COVID-19 patients in our country are managed in line
with the national treatment guideline, regularly updated
by the scientific committee established by the Ministry of
Health. LPV/RTV was used as an antiviral in some patients,
and favipiravir was used in others due to changes in the
national guideline published for COVID-19 treatment1.
Tocilizumab, systemic corticosteroid, or convalescent
plasma was also administered to patients with disease
progression despite administration of antiviral treatment.
Those administered with these treatments were also
included in the study. COVID-19 was diagnosed using
PCR or clinical, laboratory, and radiological findings.
Patients who are younger than 18 years, pregnant,
breastfeeding, and using hydroxychloroquine concurrently
were excluded.
The ethics committee approved this study according
to the rules of our institute (Ethical approval number:
2020/8/8) and the Ministry of Health.
2.1. Statistical analysis
Data were analyzed using the IBM SPSS v: 25.0 package
program. Continuous measurements were presented
as mean ± standard deviation if they were normally
distributed or median (with minimum and maximum).
However, if the continuous measurements were not
normally distributed, categorical variables were presented
as counts (%). Independent sample T test was used to
compare qualitative variables with two categories and
quantitative variables, and chi-squared test was used to
compare two categorical variables. Logistic regression
analysis was performed by including variables with
significant differences as a result of paired comparisons

into the model. Type I error rate was taken as 0.05 in the
study.
3. Results
The mean age of the patients was 56 ± 16 years, and 142
(69.6%) of them were male. In addition, 124 (60.8%)
patients had at least one concomitant chronic disease.
LPV/RTV, favipiravir, and favipiravir and LPV/RTV were
administered to 59 (28.9%), 131 (64.2%), and 14 patients,
respectively. No significant difference was found in terms
of age, sex, presence of comorbidity, and use of tocilizumab,
systemic corticosteroid, and convalescent plasma therapy
between patient groups who were administered different
treatment regimens. During their follow-up, 27 (13.2%)
patients needed to ICU. The mortality rate was 10.8%
(22/204). The duration of hospital stays in the group
administered with both drugs was significantly higher
than that in groups administered with LPV/RTV and
favipiravir alone (Table 1).
The mean age of the patients who died was 71 ± 14.3
years, which was significantly higher than that of survivors
(54.2 ± 15.5 years). The laboratory results of the two groups
showed that CK-MB, AST, CRP, LDH, and creatinine
levels were higher in the patients who died, whereas their
lymphocyte count was lower. Although age, AST, CRP,
LDH, and neutrophil counts were higher, eosinophil and
lymphocyte counts were significantly lower in patients
who needed ICU than those who did not (Table 2).
ICU requirement and mortality rates were lower in
patients administered with favipiravir compared with those
administered with LPV/RTV or LPV/RTV plus favipiravir.
When ICU need and mortality rates were compared, no
significant difference in presence of comorbidity, sex,
and use of tocilizumab, systemic corticosteroid, and
convalescent plasma was found between the groups (Table
3–4).
In logistic regression analysis, each one-unit
increase in age and AST level increases the risk of ICU
need by 1.067 and 1.018 times, respectively. Each oneunit increase in age and CK-MB levels increased the
risk of death by 1.137 and 1.036 times, respectively.
As a result of the logistic regression analysis, the treatment
regimens used were not seen as an independent risk
factor for the development of ICU need. Only the use of
favipiravir reduced mortality independently (p = 0.006)
(Table 5–6). Favipiravir use had an 8.33–fold protective
factor for mortality compared with LPV/RTV use.
4. Discussion
In this retrospective observational study that evaluated the
difference in efficacy between favipiravir and LPV/RTV in

T. C. Ministry of Health, General Directorate of Public Health. COVID-19 (SARS-CoV2 Infection) Guide (Science Board Study) (online) March 11,
2020. Website www.hsgm.saglik.gov.tr [accessed 11 March 2020].
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Table 1. Comparison of the clinical characteristics of the patients according to the treatments.
LPV/RTV
Age (mean ± SD)
54.5 ± 15.8
Male
41 (28.9)
Female
18 (29)
Comorbidities (n, %)
Absent
23 (28.7)
Present
36 (29)
Tocilizumab treatment (n, %)
No
58 (29.9)
Yes
1 (10)
Convalescent plasma treatment (n, %)
No
58 (29.6)
Yes
1 (12.5)
Systemic corticosteroid treatment (n, %)
No
59 (30.1)
Yes
0 (0)
Length of hospitalization
10.25 ± 4.89

Favipravir

LPV/RTV +
Favipravir

55.97 ± 16.6
90 (63.4)
41 (66.1)

62 ± 13.5
11 (7.7)
3 (4.8)

142 (100)
62 (100)

0.480

0.853

55 (68.8)
76 (61.3)

2 (2.5)
12 (9.7)

80 (100)
124 (100)

4.077

0.128

122 (62.9)
9 (90)

14 (7.2)
0 (0)

194 (100)
10 (100)

2.144

0.282

124 (63.3)
7 (87.5)

14 (7.1)
0 (0)

196 (100)
8 (100)

1.179

0.581

124 (63.3)
7 (87.5)
11.67 ± 5.97

13 (6.6)
1 (12.5)
18.43 ± 9.4

196 (100)
8 (100)

4.056

0.084

Total

Chi-Square

P
0.302

*<0.001

Table 2. Comparison of patients’ hospital admission findings in terms of ICU need and mortality.

Age
BMI
D-dimer
Troponine
CK
CK-MB
Fibrinogen
Ferritin
Procalcitonin
ALT
AST
CRP
LDH
Na
K
Creatinine
Lymphocyte#
Monocyte#
Neutrophil#
Eosinophil#
WBC
Hemoglobin
Hematocrit
Platelet#
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No need of ICU

Need of ICU

P

Survived

Dead

P

54.55 ± 16.3
27.5 ± 6.4
1.7 ± 3
93.2 ± 931
175.3 ± 212.3
23.02 ±16.3
476.43 ±141.9
360.5 ± 349.7
0.3 ± 0.82
35.5 ± 25.6
46.8 ± 26.3
93.9 ± 112.7
422.6 ± 181.8
134.9 ± 9.8
4.5 ± 1
0.9 ± 0.38
1.3 ± 0.6
0.7 ± 0.55
6.04 ± 3.9
0.06 ±0.16
8.14 ± 3.93
13.2 ± 1.9
38.8 ± 5.2
229.3 ± 81.1

65.1 ± 12.6
27.5 ± 5.6
2.03 ± 4.4
324.6 ± 1520
301.9 ± 399.5
27.9 ± 11.1
475.7 ± 238.5
488.9 ± 364.3
1.81 ± 7.9
45.7 ± 35.7
68.85 ± 48.1
149.6 ± 89.1
575.9 ± 201.8
136.8 ± 3.5
4.2 ± 0.5
0.98 ± 0.3
1.02 ± 0.6
0.6 ± 0.5
8.2 ± 5.02
0.009 ± 0.02
9.9 ± 5.01
13.01 ± 1.5
38.4 ± 3.8
201.5 ± 75.6

0.001*
0.965
0.610
0.465
0.149
0.148
0.991
0.124
0.362
0.072
0.027*
0.015*
<0.001*
0.319
0.142
0.279
0.036*
0.710
0.039*
<0.001*
0.089
0.633
0.643
0.096

54.2 ± 15.5
27.6 ± 6
1.7 ± 3.3
22.2 ± 109.5
176.1 ± 212.1
22.4 ± 15.7
476.6 ± 141.3
367.1 ± 357.5
0.29 ± 0.77
35.8 ± 25.4
46.8 ± 25.1
95 ± 111.7
429.5 ± 191.4
135.1 ± 9.7
4.4 ± 0.9
0.9 ± 0.37
1.3 ± 0.6
0.7 ± 0.55
6.13 ± 4.04
0.06 ± 0.15
8.22 ± 4.03
13.2 ± 1.8
38.9 ± 5.05
228.7 ± 80.2

71 ± 14.3
26.2 ± 8.3
1.9 ± 2.2
958.2 ± 3045.2
307.7 ± 414.3
34.1 ± 12.7
474 ± 259.4
456.9 ± 287.4
2.41 ± 8.86
45.8 ± 39
73.9 ± 55.2
152.9 ± 95.1
563.3 ± 150.6
135.54 ±3.9
4.5 ±1.1
1.06 ± 0.29
0.9 ± 0.6
0.6 ± 0.44
7.9 ± 4.66
0.03 ± 0.04
9.62 ± 4.75
13 ± 2
37.7 ± 5.07
200.6 ± 83

<0.001*
0.324
0.839
0.174
0.166
0.001*
0.971
0.345
0.311
0.251
0.033*
0.021*
0.002*
0.821
0.636
0.046*
0.011*
0.366
0.053
0.258
0.132
0.592
0.304
0.124
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Table 3. Comparison of patient characteristics and treatments in terms of intensive care need.
ICU need

Present (%)

Absent (%)

Total (%)

Male

124 (87.3)

18 (12.7)

142 (100)

Female

53 (85.5)

9 (14.5)

62 (100)

Absent

74 (92.5)

6 (7.5)

80 (100)

Present

103 (83.1)

21 (16.9)

124 (100)

No

169 (87.1)

25 (12.9)

194 (100)

Yes

8 (80)

2 (20)

10 (100)

No

171 (87.2)

25 (12.8)

196 (100)

Yes

6 (75)

2 (25)

8 (100)

No

171 (87.2)

25(12.8)

196 (100)

Yes

6 (75)

2(25)

8 (100)

LPV/RTV

122 (93.1)

9(6.9)

131 (100)

Favipiravir

48 (81.4)

11(18.6)

59 (100)

Favipiravir + LPV/RTV

7 (50)

7(50)

14 (100)

Chi-square

P

0.017

0.895

2.993

0.084

0.029

0.866

0.221

0.639

0.221

0.639

18.257

<0.001*

Sex

Comorbidity

Tocilizumab

Convalescent plasma

Steroids

Medication

Table 4. Comparison of patient characteristics and treatments in terms of mortality.
Mortality

Alive (%)

Dead (%)

Total (%)

Male

127 (89.4)

15 (10.6)

142 (100)

Female

55 (88.7)

7 (11.3)

62 (100)

Absent

76 (95)

4 (5)

80 (100)

Present

106 (85.5)

18 (14.5)

124 (100)

No

173 (89.2)

21 (10.8)

194 (100)

Yes

9 (90)

1 (10)

10 (100)

No

175 (89.3)

21 (10.7)

196 (100)

Yes

7 (87.5)

1 (12.5)

8 (100)

No

174 (88.8)

22 (11.2)

196 (100)

Yes

8 (100)

0 (0)

8 (100)

LPV/RTV

46 (78)

13 (22)

59 (100)

Favipiravir

125 (95.4)

6 (4.6)

131 (100)

Favipiravir + LPV/RTV

11 (78.6)

3 (21.4)

14 (100)

Chi-square

P

0.001

0.999

3.641

0.056

0.001

0.999

0.001

0.999

0.178

0.673

14.475

0.001*

Sex

Comorbidity

Tocilizumab

Convalescent plasma

Steroids

Medication
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Table 5. Logistic regression analysis on the risk factors associated with ICU in hospitalized patients with COVID-19
pneumonia.
B

S.E.

LPV/RTV

Wald

P

4.48

0.106

OR (95% CI)

Favipiravir

–1.101

0.579

3.622

0.057

0.332(0.107–1.033)

Favipiravir + LPV/RTV

0.139

0.793

0.031

0.861

1.149(0.243–5.432)

Age

0.065

0.022

9.005

0.003*

1.067(1.023–1.113)

AST

0.018

0.008

5.44

0.020*

1.018(1.003–1.033)

CRP

0.002

0.003

0.373

0.541

1.002(0.997–1.007)

LDH

0.002

0.001

1.71

0.191

1.002(0.999–1.005)

Lymphocyte#

0.42

0.467

0.809

0.368

1.523(0.609–3.805)

Neutrophil

0.104

0.063

2.72

0.099

1.109(0.981–1.255)

Eosinofil

–37.413

14.081

7.059

0.008*

0

Constant

–8.16

2.015

16.392

0

0

Table 6. Logistic regression analysis on the risk factors associated with mortality in hospitalized patients with COVID-19
pneumonia.
B

S.E.

Wald

P

OR (95% CI)

Age

0.129

0.035

13.855

<0.001*

1.137(1.063–1.217)

CK-MB

0.035

0.016

5.006

0.025*

1.036(1.004–1.068)

AST

0.022

0.013

3.102

0.078

1.022(0.997–1.048)

CRP

–0.001

0.004

0.074

0.786

0.999(0.99–1.007)

LDH

0.003

0.002

2.204

0.138

1.003(0.999–1.007)

Creatinine

0.184

0.657

0.078

0.779

1.202(0.332–4.352)

Lymphocyte#

–0.587

0.749

0.616

0.433

0.556(0.128–2.41)

Constant

–13.608

3.46

15.471

0

0

7.42

0.024*

LPV/RTV
Favipiravir

–2.119

0.778

7.407

0.006*

0.120(0.026–0.553)

Favipiravir + LPV/RTV

–1.332

1.034

1.658

0.198

0.264(0.035–2.004)

COVID-19 treatment, the mortality rate was found to be
lower in patients treated with favipiravir compared with
those treated with LPV/RTV. No statistically significant
difference in ICU need was found between the two drugs.
Although patients treated with favipiravir and LPV/
RTV have been analyzed for viral load and radiological
outcomes in previous studies, to the best of our knowledge,
this is the first study to examine clinical outcomes of the
two drugs, such as ICU need and mortality.
LPV and RTV are antiretroviral protease inhibitors used
in combination in the treatment of HIV since 2000. LPV is
effective against viral 3-chymotrypsin-like protease. RTV
is used together to increase the half-life of LPV through
cytochrome P450 inhibition and is effective only as a
pharmacokinetic enhancer [3]. A randomized, controlled,
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open-label study for suppression of SARS-CoV-2 in China
investigated the efficacy and safety of oral LPV/RTV in 199
adults hospitalized with severe COVID-19. In this study,
patients were randomized 1:1 to receive LPV/RTV (400
mg/100 mg) (n = 99) twice daily in addition to standard
care (n = 100) or standard care for 14 days. The study
showed no difference in clinical improvement between the
two groups. Mortality at 28 days was also similar in both
groups. No benefit beyond standard care was observed
with LPV/RTV therapy in adult patients hospitalized with
severe COVID-19 [4]. In a retrospective analysis of a small
patient group, 75% of patients with COVID-19 treated
with arbidol and LPV/RTV (16 patients) had negative
SARS-CoV-2 in nasopharyngeal samples on the 7th day
after treatment compared with those treated with LPV/
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RTV alone (35%, 17 patients) [5]. In another phase 2,
multi-center, open-label, randomized study, triple antiviral
therapy with interferon beta-1b, LPV/RTV, and ribavirin
was compared to reduce virus transmission, alleviate
symptoms, and facilitate discharge of patients with mild
to moderate COVID-19. It has been reported to be safe
and superior to LPV/RTV alone [6].
A clinical study involving 80 patients in Shenzhen
was conducted to evaluate the safety and efficacy of
favipiravir in COVID-19 treatment. In these open-label,
nonrandomized, controlled trial results, 35 patients in the
favipiravir arm had a significantly shorter viral clearance
time (median, 4 vs. 11 days; p < 0.001) compared with 45
patients in the LPV/RTV arm. Furthermore, radiological
improvement was better in the favipiravir arm (recovery
rate, 91.43% vs. 62%; p = 0.004) [7]. In another multicenter randomized clinical study, no statistically
significant difference was observed in the seven-day
clinical improvement (improvement in body temperature,
respiratory rate, oxygen saturation, and cough relief
for >72 h after treatment) between favipiravir and
umifenovir. However, in the favipiravir treatment group,
fever reduction and cough relief time were significantly
reduced [8]. In our study, no difference was observed in
terms of ICU need between the patient groups treated
with favipiravir and LPV/RTV, but favipiravir decreased
mortality 8.33 times, independently from other factors
affecting mortality.
Studies showed that the mortality rates were higher in
patients with advanced age with COVID-19 [9,11]. In our
study, advanced age was determined as an independent
risk factor for mortality, each unit increment in age
increases the mortality risk by 1.137 times.
Various laboratory parameters have been studied
as predictors of the probable course of the disease and
mortality, such as age, lymphopenia, leukocytosis, and
elevated ALT, LDH, high-sensitivity cardiac troponin
I, creatine kinase, d-dimer, serum ferritin, IL-6,
prothrombin time, and creatinine. Procalcitonin levels

have been reported to be associated with mortality [10,11].
In our study, although CRP, LDH, creatinine, and CK-MB
were elevated, and lymphocyte count was decreased in
patients who died, logistic regression analysis revealed
that only CK-MB among these laboratory parameters was
independently associated with mortality.
Our study has a few limitations. The study was
retrospective and had limited number of patients.
Furthermore, because LPV/RTV, except pregnant women,
is not any more suggested in the national guideline,
enrolling more patients from a single referral center seems
to be not possible.
In conclusion, the use of favipiravir was more effective
in reducing mortality compared with LPV/RTV in
hospitalized patients with COVID-19.
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